Literature DB >> 30737190

Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Peter Valent1, Cem Akin2, Patrizia Bonadonna3, Karin Hartmann4, Knut Brockow5, Marek Niedoszytko6, Boguslaw Nedoszytko7, Frank Siebenhaar8, Wolfgang R Sperr9, Joanna N G Oude Elberink10, Joseph H Butterfield11, Ivan Alvarez-Twose12, Karl Sotlar13, Andreas Reiter14, Hanneke C Kluin-Nelemans15, Olivier Hermine16, Jason Gotlib17, Sigurd Broesby-Olsen18, Alberto Orfao19, Hans-Peter Horny20, Massimo Triggiani21, Michel Arock22, Lawrence B Schwartz23, Dean D Metcalfe24.   

Abstract

Mast cell activation (MCA) accompanies diverse physiologic and pathologic processes and is one of the more frequently encountered conditions in medicine. MCA-related symptoms are usually mild and often transient. In such cases, histamine receptor blockers and other mediator-targeting drugs can usually control MCA. In severe cases, an MCA syndrome (MCAS) may be diagnosed. However, overt MCAS is an unusual condition, and many patients referred because of suspected MCAS are diagnosed with other diseases (autoimmune, neoplastic, or infectious) unrelated to MCA or suffer from MCA-related (eg, allergic) disorders and/or comorbidities without fulfilling criteria of an overt MCAS. These considerations are important as more and more patients are informed that they may have MCA or even MCAS without completing a thorough medical evaluation. In fact, in several instances, symptoms are misinterpreted as MCA/MCAS, and other clinically relevant conditions are not thoroughly pursued. The number of such referrals is increasing. To avoid such unnecessary referrals and to prevent misdiagnoses, we here propose a diagnostic algorithm through which a clinically relevant (systemic) MCA can be suspected and MCAS can subsequently be documented or excluded. In addition, the algorithm proposed should help guide the investigating care providers to consider the 2 principal diagnoses that may underlie MCAS, namely, severe allergy and systemic mastocytosis accompanied by severe MCA. Although validation is required, we anticipate that this algorithm will facilitate the management of patients with suspected MCAS.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Diagnostic algorithm; KIT D816V; MCAS; Mast cells; Tryptase

Mesh:

Substances:

Year:  2019        PMID: 30737190      PMCID: PMC6643056          DOI: 10.1016/j.jaip.2019.01.006

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  82 in total

Review 1.  Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function.

Authors:  M J Nadler; S A Matthews; H Turner; J P Kinet
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 2.  Mast cells and basophils.

Authors:  Lawrence B Schwartz
Journal:  Clin Allergy Immunol       Date:  2002

Review 3.  The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology.

Authors:  J P Kinet
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

4.  Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia.

Authors:  W R Sperr; J H Jordan; M Baghestanian; H P Kiener; P Samorapoompichit; H Semper; A Hauswirth; G H Schernthaner; A Chott; S Natter; D Kraft; R Valenta; L B Schwartz; K Geissler; K Lechner; P Valent
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

5.  Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study.

Authors:  R Y Lin; L B Schwartz; A Curry; G R Pesola; R J Knight; H S Lee; L Bakalchuk; C Tenenbaum; R E Westfal
Journal:  J Allergy Clin Immunol       Date:  2000-07       Impact factor: 10.793

6.  Multiple defects in Fc epsilon RI signaling in Syk-deficient nonreleaser basophils and IL-3-induced recovery of Syk expression and secretion.

Authors:  C L Kepley; L Youssef; R P Andrews; B S Wilson; J M Oliver
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

7.  Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms.

Authors:  P Samorapoompichit; H P Kiener; G H Schernthaner; J H Jordan; H Agis; F Wimazal; M Baghestanian; A Rezaie-Majd; W R Sperr; K Lechner; P Valent
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

8.  Serum tryptase measurements in patients with myelodysplastic syndromes.

Authors:  W R Sperr; B Stehberger; F Wimazal; M Baghestanian; L B Schwartz; M Kundi; H Semper; J H Jordan; A Chott; J Drach; U Jäger; K Geissler; A Greschniok; H P Horny; K Lechner; P Valent
Journal:  Leuk Lymphoma       Date:  2002-05

9.  Recombinant allergens promote expression of CD203c on basophils in sensitized individuals.

Authors:  Alexander W Hauswirth; Susanne Natter; Minoo Ghannadan; Yasamin Majlesi; Gerit-Holger Schernthaner; Wolfgang R Sperr; Hans-Jörg Bühring; Rudolf Valenta; Peter Valent
Journal:  J Allergy Clin Immunol       Date:  2002-07       Impact factor: 10.793

Review 10.  Association of the Src homology 2 domain-containing inositol 5' phosphatase (SHIP) to releasability in human basophils.

Authors:  Susan M MacDonald; Becky M Vonakis
Journal:  Mol Immunol       Date:  2002-09       Impact factor: 4.407

View more
  36 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 2.  Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

Authors:  Peter Valent; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Massimo Triggiani; Jonathan J Lyons; Joanna N G Oude Elberink; Michel Arock; Dean D Metcalfe; Cem Akin
Journal:  Int Arch Allergy Immunol       Date:  2019-06-28       Impact factor: 2.749

3.  Anaphylaxis knowledge gaps and future research priorities: A consensus report.

Authors:  Timothy E Dribin; David Schnadower; Julie Wang; Carlos A Camargo; Kenneth A Michelson; Marcus Shaker; Susan A Rudders; David Vyles; David B K Golden; Jonathan M Spergel; Ronna L Campbell; Mark I Neuman; Peter S Capucilli; Michael Pistiner; Mariana Castells; Juhee Lee; David C Brousseau; Lynda C Schneider; Amal H Assa'ad; Kimberly A Risma; Rakesh D Mistry; Dianne E Campbell; Margitta Worm; Paul J Turner; John K Witry; Yin Zhang; Brad Sobolewski; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2021-08-12       Impact factor: 10.793

Review 4.  Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice.

Authors:  Polliana Mihaela Leru
Journal:  Cureus       Date:  2022-02-13

Review 5.  Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond.

Authors:  Sarah C Glover; Melody C Carter; Peter Korošec; Patrizia Bonadonna; Lawrence B Schwartz; Joshua D Milner; George H Caughey; Dean D Metcalfe; Jonathan J Lyons
Journal:  Ann Allergy Asthma Immunol       Date:  2021-08-13       Impact factor: 6.248

6.  Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders.

Authors:  Michael Kurin; Abbinaya Elangovan; Muhammed Mustafa Alikhan; Basmah Al Dulaijan; Eli Silver; David C Kaelber; Gregory Cooper
Journal:  Neurogastroenterol Motil       Date:  2021-09-17       Impact factor: 3.960

Review 7.  Sinus Tachycardia: a Multidisciplinary Expert Focused Review.

Authors:  Kenneth A Mayuga; Artur Fedorowski; Fabrizio Ricci; Rakesh Gopinathannair; Jonathan Walter Dukes; Christopher Gibbons; Peter Hanna; Dan Sorajja; Mina Chung; David Benditt; Robert Sheldon; Mirna B Ayache; Hiba AbouAssi; Kalyanam Shivkumar; Blair P Grubb; Mohamed H Hamdan; Stavros Stavrakis; Tamanna Singh; Jeffrey J Goldberger; James A S Muldowney; Mark Belham; David C Kem; Cem Akin; Barbara K Bruce; Nicole E Zahka; Qi Fu; Erik H Van Iterson; Satish R Raj; Fetnat Fouad-Tarazi; David S Goldstein; Julian Stewart; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-09-08

8.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

9.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

10.  Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.

Authors:  Georg Greiner; Bettina Sprinzl; Aleksandra Górska; Franz Ratzinger; Michael Gurbisz; Nadine Witzeneder; Klaus G Schmetterer; Bettina Gisslinger; Goekhan Uyanik; Emir Hadzijusufovic; Harald Esterbauer; Karoline V Gleixner; Maria T Krauth; Michael Pfeilstöcker; Felix Keil; Heinz Gisslinger; Boguslaw Nedoszytko; Marek Niedoszytko; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.